Astellas Pharma US, Inc.
3-11 Nihonbashi-Honcho 2-chome
About Astellas Pharma US, Inc.
527 articles with Astellas Pharma US, Inc.
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
The experimental drug enfortumab vedotin, developed by Astellas and Seattle Genetics, demonstrated a 44% objective response rate in patients.
Astellas Oncology Announces C³ Prize® Call for Entries to Award $200,000 to the Best Ideas in Cancer Care Beyond Medicine
Astellas Pharma US, Inc. announced the call for entries for the fourth annual Astellas Oncology C3 Prize, a challenge that funds the best non-treatment ideas to improve cancer care for patients, caregivers and their loved ones.
The federal anti-kickback statute prevents pharmaceutical companies from providing financial coverage of Medicare copay payments that would encourage patients to purchase a company’s medication.
During a presentation at the American Association for Cancer Research meeting over the weekend, Astellas touted new overall survival data for Xospata.
Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated
Actinium's AWE Technology Platform is Being Applied to Generate Antibody Radiation-Conjugates with Select Astellas Targeting Agents
Seattle Genetics and Tokyo-based Astellas Pharma announced positive topline data from the first cohort of its Phase II EV-201 trial.
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
Joint Project Will Explore Enhancements to Patient Communication and Shared Decision-Making
The American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) is being held in San Francisco from February 14-16. Ahead of the conference, several companies have announced presentations. Here’s a look at just a few.
Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization
Astellas is pleased to announce three recent senior-level promotions and one new hire within its Medical and Development (M&D) organization. E
Astellas today announced that Lei Ding has been promoted to vice president, Payer Strategy, Contracts and Pricing.
The FDA approved Xospata for adult AML patients who have a FLT3 mutation as detected by an FDA-approved test. Of the 19,000 people in the United States who are estimated to be diagnosed with AML this year, nearly 40 percent will have a FLT3 mutation.
Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce Collaboration
Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) announced today a new collaboration to develop, standardize and validate an evidence-based, oncology navigation-specific Acuity Tool.
Astellas today announced that Eloiza Domingo-Snyder has been appointed to executive director of Diversity and Inclusion, Astellas US.
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
Astellas Details Progress and Commitment to Patients and the Community in the Company's Americas 2017 Corporate Social Responsibility Report Card
Astellas today issued its third-annual Americas Corporate Social Responsibility (CSR) Report Card.
Astellas Oncology Announces Grand Prize Winner of C3 Prize® at Union for International Cancer Control (UICC) World Cancer Congress
Three innovators working to change cancer care awarded a combined $100,000 in grants following live pitch to a panel of judges that included celebrity entrepreneur Bill Rancic
Apotheker Group Executive Search and Advisory Services Firm Celebrates its Launch and Honors Recently Appointed ACMA Board of Governors
Apotheker Group, Search and Advisory, an Executive Search & Advisory firm specializing in the life sciences industry, is hosting an invite-only event on Thursday, October 4th, 2018 at the Dream Downtown Hotel in Manhattan, NY to celebrate its recent launch as well as the newly appointed ACMA Board of Governors.